In touch with psoriasis: topical treatments and current guidelines.
Affiliation
National Photobiology Unit Beaumont & Mater Hospitals, Dermatology Department,, Beaumont Hospital, Dublin, Ireland. gillianmmurphy@gmail.comIssue Date
2012-02-01T09:59:25ZMeSH
Administration, TopicalBetamethasone/administration & dosage/analogs & derivatives/therapeutic use
Calcitriol/administration & dosage/analogs & derivatives/therapeutic use
Dermatologic Agents/administration & dosage/*therapeutic use
Humans
*Practice Guidelines as Topic
Psoriasis/*drug therapy
Metadata
Show full item recordCitation
J Eur Acad Dermatol Venereol. 2011 Jun;25 Suppl 4:3-8. doi:, 10.1111/j.1468-3083.2011.04059.x.Journal
Journal of the European Academy of Dermatology and Venereology : JEADVDOI
10.1111/j.1468-3083.2011.04059.xPubMed ID
21507077Abstract
This article describes topical therapies and treatment guidelines for psoriasis and is based on a presentation given by the authors at a satellite symposium held during the 19th Congress of the European Academy of Dermatology and Venereology, 6-10 October, 2010, in Gothenburg, Sweden. The highly variable nature of psoriasis and its individual presentation in patients can make it difficult to choose the most appropriate treatment. There are many treatment options, from topical treatment with emollients for very mild psoriasis, to systemic therapy with fumaric acid esters, methotrexate or biologics for severe disease. For the treatment of mild-to-moderate psoriasis, topical therapy is generally the most appropriate and a variety of options, both historical and recent, are available. Newer therapies offer greater convenience and fewer side-effects. Of the more recently available therapies, vitamin D analogues and topical corticosteroids are the two with the greatest proven efficacy in randomized clinical trials. A recent Cochrane review showed the highest efficacy overall with the fixed combination vitamin D analogue (calcipotriol) and corticosteroid (betamethasone dipropionate). Indeed, clinical trials have shown that two-compound calcipotriol/betamethasone dipropionate ointment has higher efficacy than calcipotriol or betamethasone dipropionate alone. With regard to safety, two-compound calcipotriol/betamethasone dipropionate was shown to be suitable for intermittent long-term treatment of mild-to-moderate psoriasis. The findings of the Cochrane review are reflected in the current treatment guidelines from the USA and Germany regarding the treatment of mild-to-moderate psoriasis. In both these guidelines, which will be discussed in this article, the recommended treatments for this patient group are vitamin D analogues and corticosteroids, particularly when used in combination.Language
engISSN
1468-3083 (Electronic)0926-9959 (Linking)
ae974a485f413a2113503eed53cd6c53
10.1111/j.1468-3083.2011.04059.x
Scopus Count
Collections
Related articles
- What is new in topical therapy for psoriasis?
- Authors: Reich K, Bewley A
- Issue date: 2011 Jun
- Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial.
- Authors: Kragballe K, Hoffmann V, Ortonne JP, Tan J, Nordin P, Segaert S
- Issue date: 2009 Jul
- Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris.
- Authors: Kragballe K, Noerrelund KL, Lui H, Ortonne JP, Wozel G, Uurasmaa T, Fleming C, Estebaranz JL, Hanssen LI, Persson LM
- Issue date: 2004 Jun
- Consensus on the use of the fixed combination calcipotriol/betamethasone dipropionate in the treatment of plaque psoriasis.
- Authors: Girolomoni G, Vena GA, Ayala F, Cannavò SP, De Pità O, Chimenti S, Peserico A
- Issue date: 2012 Dec
- The two-compound formulation of calcipotriol and betamethasone dipropionate for treatment of moderately severe body and scalp psoriasis - an introduction.
- Authors: Freeman K
- Issue date: 2011 Jan